Raludotatug deruxtecan

Recent findings demonstrate that folate receptor-alpha expression levels strongly correlate with mirvetuximab soravtansine-gynx efficacy in ovarian cancer treatment, showing highest activity in patients with high expression.

The treatment landscape for platinum-resistant ovarian cancer is evolving, with refined definitions of platinum resistance influencing treatment strategies.

Daiichi Sankyo and Merck have expanded their existing partnership to include MK-6070, an investigational DLL3-targeting T-cell engager, with Merck receiving $170 million upfront in the agreement.

The FDA has approved AstraZeneca's Voydeya (danicopan) as an add-on therapy for extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Merck will pay Daiichi Sankyo $4 billion upfront plus $1.5 billion in continuation payments, with potential additional milestone payments reaching a total of $22 billion.